A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.

Phase 1

Merck Sharp & Dohme Corp.

Famotidine
Omeprazole
Raltegravir Potassium